68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs

Rudolf A. Werner; Christina Bluemel; Martin S. Allen-Auerbach; Takahiro Higuchi; Ken Herrmann

doi:10.1007/s12149-014-0898-6

⁶⁸Gallium- and ⁹⁰Yttrium-/¹⁷⁷Lutetium: “theranostic twins” for diagnosis and treatment of NETs

Rudolf A. Werner, Christina Bluemel, Martin S. Allen-Auerbach, Takahiro Higuchi, Ken Herrmann

Research output: Contribution to journal › Article › peer-review

56 Citations (Scopus)

Abstract

Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.

Original language	English
Pages (from-to)	1-7
Number of pages	7
Journal	Annals of nuclear medicine
Volume	29
Issue number	1
DOIs	https://doi.org/10.1007/s12149-014-0898-6
Publication status	Published - Jan 1 2015
Externally published	Yes

Keywords

Neuroendocrine tumor
PET/CT
PRRT
Radionuclide therapy
SPECT/CT
Theranostic

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s12149-014-0898-6

Cite this

@article{8707cd1595bf4ce8b5a75378424c2a9f,

title = "68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs",

abstract = "Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.",

keywords = "Neuroendocrine tumor, PET/CT, PRRT, Radionuclide therapy, SPECT/CT, Theranostic",

author = "Werner, {Rudolf A.} and Christina Bluemel and Allen-Auerbach, {Martin S.} and Takahiro Higuchi and Ken Herrmann",

note = "Publisher Copyright: {\textcopyright} 2014, The Japanese Society of Nuclear Medicine.",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/s12149-014-0898-6",

language = "English",

volume = "29",

pages = "1--7",

journal = "Annals of Nuclear Medicine",

issn = "0914-7187",

publisher = "Springer Japan",

number = "1",

}

TY - JOUR

T1 - 68Gallium- and 90Yttrium-/177Lutetium

T2 - “theranostic twins” for diagnosis and treatment of NETs

AU - Werner, Rudolf A.

AU - Bluemel, Christina

AU - Allen-Auerbach, Martin S.

AU - Higuchi, Takahiro

AU - Herrmann, Ken

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.

AB - Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.

KW - Neuroendocrine tumor

KW - PET/CT

KW - PRRT

KW - Radionuclide therapy

KW - SPECT/CT

KW - Theranostic

UR - http://www.scopus.com/inward/record.url?scp=84939894859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939894859&partnerID=8YFLogxK

U2 - 10.1007/s12149-014-0898-6

DO - 10.1007/s12149-014-0898-6

M3 - Article

C2 - 25139472

AN - SCOPUS:84939894859

SN - 0914-7187

VL - 29

SP - 1

EP - 7

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

IS - 1

ER -